What is SEMA GLP-1 (S)?
SEMA GLP-1 (S) is a synthetic analogue of the human GLP-1 hormone, designed to bind and activate the GLP-1 receptor. This activation promotes glucose-dependent insulin secretion and inhibits glucagon release, aiding in blood sugar regulation. Additionally, it slows gastric emptying, leading to increased satiety and potential weight loss. Due to its extended half-life, it is administered once weekly, offering a convenient dosing regimen for research purposes. This compound is intended solely for scientific investigation and is not approved for human or veterinary use.
As semaglutide, this compound is FDA-approved under the brand names Ozempic and Rybelsus for type 2 diabetes and Wegovy for chronic weight management.
Structure
- Chemical Formula: C187H291N45O59
- Synonyms: NN9535, Ozempic, Rybelsus, Wegovy
SEMA GLP-1 (S) Research
Type 2 Diabetes Management
Clinical trials have demonstrated that SEMA GLP-1 (S) significantly improves glycemic control in individuals with type 2 diabetes. In the SUSTAIN-6 trial, it reduced HbA1c levels and was associated with a lower rate of major adverse cardiovascular events compared to placebo. These findings suggest its potential role in comprehensive diabetes management. [1]
Weight Management
Research indicates that it may be effective in promoting weight loss among individuals with obesity. A study published in The New England Journal of Medicine reported that participants receiving it experienced significant weight reduction compared to those on placebo. This effect is attributed to its action on appetite regulation and energy intake[2]
Cardiovascular Outcomes
SEMA GLP-1 (S) has been evaluated for its impact on cardiovascular outcomes in patients with type 2 diabetes. The SUSTAIN-6 trial demonstrated a significant reduction in the risk of major adverse cardiovascular events among participants treated with it. These results highlight its potential cardiovascular benefits beyond glycemic control [3]
Non-Alcoholic Steatohepatitis (NASH)
Emerging studies suggest that it may have therapeutic potential in treating non-alcoholic steatohepatitis (NASH). Clinical trials have shown improvements in liver enzyme levels and reductions in liver fat content among patients with NASH treated with it, indicating a possible role in managing this condition [4]
Reconstitution and dosing
GLP-1 (S) / SEMA / Semaglutide is typically reconstituted with Bacteriostatic water at 5mg/ml to 10mg/ml. Dosing varies widely depending on the individual, their experience with GLP-1 agonists and how quickly they want to achieve fat loss. Because GLP-1 (S) is an older, less refined peptide, we recommend that users start with 250mcg/wk to avoid negative side effects. Most users will follow a titration schedule. In our experience working with clients, rather than continuing to titrate up to higher and higher doses, we encourage users to switch over to GLP-2 (T) or GLP-3 (R) as their progress slows and they find they need a higher dose to continue to achieve results.
For our free Peptide Calculator, CLICK HERE. Research-grade SEMA GLP-1 (S) is available from WellnessPeptides.
Disclaimer
ALL ARTICLES AND PRODUCT INFORMATION PROVIDED ON THIS WEBSITE ARE FOR INFORMATIONAL AND EDUCATIONAL PURPOSES ONLY.
Referenced Citations
- Marso SP, Daniels GH, Brown-Frandsen K, et al. “SEMA GLP-1 (S) and Cardiovascular Outcomes in Patients with Type 2 Diabetes.” The New England Journal of Medicine. 2016;375(19):1834–1844. Available at: https://www.nejm.org/doi/full/10.1056/NEJMoa1607141
- Wilding JPH, Batterham RL, Calanna S, et al. “Once-Weekly SEMA GLP-1 (S) in Adults with Overweight or Obesity.” The New England Journal of Medicine. 2021;384(11):989–1002. Available at: https://www.nejm.org/doi/full/10.1056/NEJMoa2032183
- Marso SP, Bain SC, Consoli A, et al. “SEMA GLP-1 (S) and Cardiovascular Outcomes in Patients with Type 2 Diabetes.” The New England Journal of Medicine. 2016;375(19):1834–1844. Available at: https://www.nejm.org/doi/full/10.1056/NEJMoa1607141
- Newsome PN, Buchholtz K, Cusi K, et al. “A Placebo-Controlled Trial of Subcutaneous SEMA GLP-1 (S) in Nonalcoholic Steatohepatitis.” The New England Journal of Medicine. 2021;384(12):1113–1124. Available at: https://www.nejm.org/doi/full/10.1056/NEJMoa2028395
